Hemogenyx Pharmaceuticals Plc (LON: HEMO)

Market Cap	12.03M
Revenue (ttm)	n/a
Net Income (ttm)	-5.18M
Shares Out	3.50M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,237
Open	333.00
Previous Close	343.40
Day's Range	333.00 - 354.95
52-Week Range	270.00 - 2,853.60
Beta	3.15
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hema...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 17
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HEMO